Tezosentan is a non-selective ET_A and ET_B receptor antagonist. It acts as a vasodilator and was designed by Actelion as a therapy for patients with acute heart failure. However, studies showed that tezosentan did not improve

dyspnea Shortness of breath (SOB), also medically known as dyspnea (in AmE) or dyspnoea (in BrE), is an uncomfortable feeling of not being able to breathe well enough. The American Thoracic Society defines it as "a subjective experience of breathing di ...

or reduce the risk of fatal or nonfatal cardiovascular events.

References

Vasodilators Tetrazoles Pyridines Pyrimidines Phenol ethers Sulfonamides Alcohols Endothelin receptor antagonists Isopropyl compounds Diaryl ethers {{cardiovascular-drug-stub